Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial
Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial. // Clinical Nutrition. – URL: https://www.sciencedirect.com/science/article/pii/S0261561426002736?dgcid=rss_sd_all
Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial. Clinical Nutrition. https://www.sciencedirect.com/science/article/pii/S0261561426002736?dgcid=rss_sd_all
“Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial.” Clinical Nutrition.
@article{article41520,
title = {Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial},
journal = {Clinical Nutrition},
url = {https://www.sciencedirect.com/science/article/pii/S0261561426002736?dgcid=rss_sd_all}
}